Hepatic metabolic clearance of midazolam, a cytochrome P450 3A substrate, in the presence of ketoconazole in rats

Pharmacy and Pharmacology Communications

Volumn 5, Issue 8, 1999, Pages 529-536

  Higashikawa, Fumiko ^a   Murakami, Teruo ^a   Makino, Misao ^a   Takano, Mikihisa ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXAMETHASONE; ENZYME INHIBITOR; KETOCONAZOLE; MIDAZOLAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG PROTEIN BINDING; ENZYME SUBSTRATE; HEPATIC VEIN; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; LIVER MICROSOME; NONHUMAN; PORTAL VEIN; RAT;

EID: 0032871518     PISSN: 14608081     EISSN: None     Source Type: Journal    
DOI: 10.1211/146080899128735207     Document Type: Article

References (20)

1. Backman, J. T., Olkkola, K. T., Neuvonen, P. J. (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59: 7-13
2. Bass, L., Keiding, S. (1988) Physiologically based models and strategic experiments in hepatic pharmacology. Biochem. Pharmacol. 37: 1425-1431
3. Dedrick, R. L., Forester, D. D., Cannon, J. N., El Dareen, S. M., Mellett, L. B. (1973) Pharmacokinetics of 1-β-D-arabinofuranosylcytosine (Ara-C) deamination in several species. Biochem. Pharmacol. 22: 2405-2417
4. Ghosal, A., Satoh, H., Thomas, P. E., Bush, E., Moore, D. (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab. Dispos. 24: 940-947
5. Gorski, J. C., Hall, S. D., Jones, D. R., VandenBranden, M., Wrighton, S. A. (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47: 1643-1653
6. Higashikawa, F., Murakami, T., Kaneda, T., Kato, A., Takano, M. (1999a) Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate, in rats with differently modulated enzyme activity. J. Pharm. Pharmacol. 51: 67-72
7. Higashikawa, F., Murakami, T., Kaneda, T., Takano, M. (1999b) In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P-450 3A substrate, by the liver under normal and increased enzyme activity in rats. J. Pharm. Pharmacol. 51: 405-410
8. Ito, K., Iwatsubo, T., Kanamitsu, S., Nakajima, Y., Sugiyama, Y. (1998a) Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu. Rev. Pharmacol. Toxicol. 38: 461-499
9. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., Sugiyama, Y. (1998b) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50: 387-412
10. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Sugiyama, Y. (1996) Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Disposit. 17: 273-310
11. Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., Sugiyama, Y. (1997) Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73: 147-171
12. Kupferschmidt, H. H., Ha, H. R., Ziegler, W. H., Meier, P. J., Krahenbuhl, S. (1995) Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58: 20-28
13. Lee, P. C., Werlin, S. L. (1995) The induction of hepatic cytochrome P450 3A in rats: effects of age. Proc. Soc. Exp. Biol. Med. 210: 134-139
14. Mahnke, A., Roos, P. H., Hanstein, W. G., Chabot, G. G. (1996) In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. Biochem. Pharmacol. 51: 1579-1582
15. Montandon, B., Roberts, R. J., Fisher, L. J. (1975) Computer simulation of sulfobromophtalein kinetics in the rat using flow-limited models with extrapolation to man. J. Pharmacokinet. Biopharm. 3: 277-290
16. Olkkola, K. T., Backman, J. T., Neuvonen, P. J. (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin. Pharmacol. Ther. 55: 481-485
17. Roberts, M. S., Rowland, M. (1986) A dispersion model of hepatic elimination: 1. formulation of the model and bolus considerations. J. Pharmacokinet. Biopharm. 14: 227-260
18. Tucker, G. T. (1992) The rational selection of drug interaction studies: implications of recent advances in drug metabolism. Int. J. Clin. Pharmacol. Ther. Toxicol. 30: 550-553
19. von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S. X., Harrel, L. M., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., Shader, R. I. (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276: 370-379
20. Wrighton, S. A., Ring, B. J. (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm. Res. 11: 921-924